Why It Matters
A new Washington state law targeting prescription drug pricing has triggered a pair of federal lawsuits from two of the world’s largest pharmaceutical manufacturers, putting the future of a decades-old federal discount drug program in legal jeopardy just weeks before it is set to take effect. The outcome could have significant implications for safety-net hospitals and community health centers across the Pacific Northwest, including rural and low-income clinics in neighboring Idaho that rely on the federal 340B program to offset care costs.
With deep federal Medicaid cuts already anticipated, the dispute comes at a particularly sensitive moment for providers who serve uninsured and low-income patients throughout the region.
What Happened
On Wednesday, March 26, 2026, Washington Governor Bob Ferguson signed Senate Bill 5981, a measure aimed at increasing transparency within the federal 340B drug pricing program and prohibiting drug manufacturers from restricting which pharmacies can dispense their discounted medications to eligible patients.
The same day the bill was signed, pharmaceutical companies Novartis and AbbVie filed separate lawsuits against the state in federal court in western Washington. Both companies allege the new law will not achieve its stated goal of lowering prescription costs for patients and that enforcement of the measure would cause them significant financial harm, with each company reportedly standing to lose millions of dollars annually.
SB 5981 passed the Washington State Senate strictly along party lines, with Democrats in support. It received some bipartisan backing in the House. The law is scheduled to take effect in June 2026.
Prior to signing, Governor Ferguson received veto requests from AbbVie, Pfizer, AstraZeneca, the Building Industry Association of Washington, and the National Federation of Independent Business. He also received letters of support, including from the Moses Lake Community Health Center, whose CEO argued the 340B program funds chronic disease care and mental health services for underserved patients.
Understanding the 340B Program
The federal 340B drug pricing program was established in 1992. It requires pharmaceutical manufacturers to provide heavily discounted outpatient medications to qualifying safety-net providers, including rural hospitals and clinics that disproportionately serve low-income or uninsured patients.
Those providers are permitted to bill insurers at standard market rates, with the difference in revenue helping to fund expanded care services for vulnerable populations. Supporters argue this structure is essential to keeping safety-net providers financially viable. Critics, including the pharmaceutical industry, contend that the savings do not always flow directly to patients.
By the Numbers
- Billions of dollars in pharmaceutical drugs are distributed annually through the federal 340B program nationwide.
- Two major pharmaceutical companies — Novartis and AbbVie — have each filed separate federal lawsuits against Washington state.
- The law passed the Washington Senate along strict party lines; it cleared the House with some Republican support.
- The legislation is set to take effect in June 2026, pending the outcome of the ongoing legal challenges.
- At least five organizations and companies, including three major pharmaceutical firms, formally requested a gubernatorial veto before the bill was signed.
Zoom Out
Washington is not the first state to pursue 340B-related legislation, and courts in other states have largely upheld similar laws when challenged by pharmaceutical manufacturers. The legal battles, however, continue to multiply as drug companies push back on state-level efforts to regulate how the program operates.
The timing adds a layer of urgency to the dispute. Hospitals and community health centers across the Mountain West and Pacific Northwest are already bracing for anticipated reductions in federal Medicaid funding. For rural providers in states like Idaho and Montana, the 340B program represents a critical financial buffer, making the Washington legal fight closely watched by health care administrators throughout the region.
The broader national debate over prescription drug pricing transparency shows no sign of slowing, with multiple states weighing similar legislation even as the pharmaceutical industry mounts legal defenses against existing measures.
What’s Next
The federal lawsuits filed by Novartis and AbbVie will proceed through the U.S. District Court for the Western District of Washington. Legal observers expect the companies to seek a preliminary injunction to block the law from taking effect in June while litigation continues.
Washington state attorneys are expected to defend the legislation, pointing to precedents from other states where comparable 340B measures survived court challenges. The outcome of this case could either accelerate or slow similar legislative efforts in Idaho and other states considering 340B reform measures of their own.
About the Author
